The New Era of Weight Loss Medications: GLP-1s, Mental Health, and the Medicalization of Obesity

Dr. Tracey Marks discusses the evolving landscape of weight loss, emphasizing that obesity, classified as a medical disorder since 2013, is a complex issue beyond simple lifestyle choices. She highlights the significant prevalence of obesity in the US and its particular impact on individuals with mental health conditions, where disorders like depression and trauma, as well as psychiatric medications (notably atypical antipsychotics and antidepressants), can directly contribute to weight gain by altering appetite, metabolism, and fat storage. The episode traces the history of anti-obesity medications, from the problematic Fen-phen to older drugs like Contrave and Metformin, which offered modest weight loss, setting the stage for a new generation of more effective treatments.

The core of the discussion revolves around Glucagon-Like Peptide-1 Receptor Agonists (GLP-1s), such as liraglutide (Saxenda), semaglutide (Wegovy, Ozempic), and tirzepatide (Mounjaro). Dr. Marks explains their multi-faceted mechanisms: reducing appetite, slowing gastric emptying to prolong satiety, increasing insulin secretion, and uniquely, stimulating brown fat to burn white fat for fuel. This brown fat activation is presented as a key differentiator from older medications. She details the FDA approvals for these drugs, distinguishing between those approved for obesity (Wegovy) and those primarily for type 2 diabetes (Ozempic, Mounjaro), and outlines the BMI criteria and co-morbidities required for insurance coverage.

Practical insights include the common side effects (gastrointestinal issues, gallstones from rapid weight loss), contraindications (liver/kidney disease), and crucial metabolic benefits beyond weight loss, such as improved lipid profiles, fasting glucose, A1C, and blood pressure. Dr. Marks stresses the importance of a thorough doctor consultation, including initial blood work to assess liver and kidney function, and a medication interaction check. She also addresses significant barriers to treatment, particularly the high cash price ($1,000-$1,400/month) and strict insurance requirements, as well as the need for long-term use and the injectable nature of most GLP-1s.

Broader implications include the paradigm shift from blaming individuals for weight gain to recognizing obesity as a treatable medical condition. Dr. Marks advocates for using these medications as a tool to facilitate significant, sustainable lifestyle changes, particularly dietary shifts towards nutrient-rich, real foods, which become easier with the appetite-modulating effects of the drugs. The goal is not just weight loss, but a fundamental change in eating habits and cravings to prevent weight regain, ultimately improving overall metabolic and mental health outcomes for patients, especially those on psychiatric medications. She also cautions against rapid weight loss due to aesthetic and health downsides like gallstones and a gaunt appearance. The episode concludes by promoting her mental wellness community for deeper insights and resources.

Did you know that more than a third of people in the United States meet the criteria for being obese?

As of 2013, obesity has been classified as a medical disorder because it causes lots of other medical complications.

until recently, helping someone lose weight was just saying eat less and exercise more. But this isn't the real answer because weight gain is complicated.

The biggest offenders are the atypical antipsychotics and then second in line would be the antidepressants.

These newer drugs are called glucagon-like peptide-1 receptor agonists or GLP-1s for short.

When brown fat gets activated, it burns white fat for fuel, so these drugs indirectly cause body fat loss by activating brown adipose tissue.

These GLP drugs have been shown in studies to result in 10 to 22% weight loss as opposed to the 5 to 10 from the older drugs.

A huge barrier to treatment though is cost. Insurance can get very nitpicky about showing proof that you qualify medically and that you've tried some of the other cheaper medications first.

If you stop after a couple of months, you can gain the weight back especially if you haven't changed your eating habits.

The diet changes are not calorie restriction but eating real food that's rich in nutrients.